Published in Semin Oncol on October 01, 1996
Addition of Gemcitabine to Pre Allo-HSCT Conditioning for Acute Lymphoblastic Leukemia | NCT03339700
Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res (2008) 2.58
Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer (2007) 1.87
Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients. Int J Clin Oncol (2011) 1.62
Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors. Ann Oncol (2015) 1.39
Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene (2009) 1.37
Identification of novel cellular targets in biliary tract cancers using global gene expression technology. Am J Pathol (2003) 1.33
Exploiting replicative stress to treat cancer. Nat Rev Drug Discov (2015) 1.27
Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer. Chem Rev (2009) 1.06
Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant (2012) 0.95
Kinetic investigation of the inhibitory effect of gemcitabine on DNA polymerization catalyzed by human mitochondrial DNA polymerase. J Biol Chem (2008) 0.94
Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer. J Thorac Oncol (2010) 0.93
High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. Biol Blood Marrow Transplant (2012) 0.92
Structural and biochemical studies of a fluoroacetyl-CoA-specific thioesterase reveal a molecular basis for fluorine selectivity. Biochemistry (2010) 0.90
Modulation of the ribonucleotide reductase M1-gemcitabine interaction in vivo by N-ethylmaleimide. Biochem Biophys Res Commun (2011) 0.88
Alpha-carboxy nucleoside phosphonates as universal nucleoside triphosphate mimics. Proc Natl Acad Sci U S A (2015) 0.86
DNA damage induced by cis- and carboplatin as indicator for in vitro sensitivity of ovarian carcinoma cells. BMC Cancer (2009) 0.86
Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions. Cancers (Basel) (2010) 0.85
A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy. PLoS One (2013) 0.84
Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer. Pharmacogenet Genomics (2012) 0.83
Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone. World J Surg Oncol (2013) 0.82
Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126. Invest New Drugs (2011) 0.82
The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines. BMC Cancer (2006) 0.82
Leucovorin, 5-fluorouracil, and gemcitabine: a phase I study. Invest New Drugs (1999) 0.81
Potential biomarkers for sensitivity of gallbladder cancer cells to gemcitabine. Int J Clin Exp Pathol (2014) 0.81
Gemcitabine plus S-1 versus cetuximab as a third-line therapy in metastatic colorectal cancer: an observational trial. Int J Clin Exp Med (2015) 0.81
A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors. Invest New Drugs (2007) 0.81
Monitoring oxygen levels in orthotopic human glioma xenograft following carbogen inhalation and chemotherapy by implantable resonator-based oximetry. Int J Cancer (2014) 0.80
Gene expression analysis for predicting gemcitabine sensitivity in pancreatic cancer patients. HPB (Oxford) (2007) 0.80
Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma. BMC Cancer (2005) 0.80
Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors. Invest New Drugs (2013) 0.80
A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma. Br J Cancer (2004) 0.79
Triplex-forming oligonucleotides targeting c-MYC potentiate the anti-tumor activity of gemcitabine in a mouse model of human cancer. Mol Carcinog (2013) 0.79
No evidence of gemcitabine accumulation during weekly administration. Eur J Clin Pharmacol (2005) 0.79
A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid. Br J Cancer (2003) 0.79
Dose intense triplet chemotherapy with gemcitabine, carboplatin, paclitaxel with peripheral blood progenitor cell support for six cycles in advanced epithelial ovarian cancer. Br J Cancer (2004) 0.78
Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies. Invest New Drugs (2010) 0.78
Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase. Cancer Chemother Pharmacol (2010) 0.78
Looking to the future: biomarkers in the management of pancreatic adenocarcinoma. Int J Mol Sci (2011) 0.78
Gemcitabine and vinorelbine combination chemotherapy in anthracycline- and taxane-pretreated advanced breast cancer. Cancer Res Treat (2008) 0.78
Successful resection of advanced pancreatic tail cancer after neoadjuvant gemcitabine chemotherapy: report of a case. Surg Today (2006) 0.77
GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type. Medicine (Baltimore) (2016) 0.77
Preclinical absorption, distribution, metabolism, and excretion of an oral amide prodrug of gemcitabine designed to deliver prolonged systemic exposure. Pharmaceutics (2013) 0.77
Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitors. Oncotarget (2015) 0.77
Achievement of complete remission in refractory Hodgkin's disease with prolonged infusion of gemcitabine. Invest New Drugs (2001) 0.76
The significance of phosphorylated heat shock protein 27 on the prognosis of pancreatic cancer. Oncotarget (2016) 0.76
Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy. Oncotarget (2016) 0.76
Treatment options in non-muscle-invasive bladder cancer after BCG failure. Indian J Urol (2015) 0.76
Hepatic arterial infusion of gemcitabine-oxaliplatin in a large metastasis from colon cancer. World J Gastroenterol (2010) 0.75
Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach. Pancreas (2016) 0.75
Gemcitabine single or combination chemotherapy in post anthracycline and taxane salvage treatment of metastatic breast cancer: retrospective analysis of 124 patients. Cancer Res Treat (2006) 0.75
Phase I and II Study of Gemcitabine and Vinorelbine in Heavily Pretreated Patients with Metastatic Breast Cancer and Review of the Literature. J Cancer (2014) 0.75
The Clinical Significance of Phosphorylated Heat Shock Protein 27 (HSPB1) in Pancreatic Cancer. Int J Mol Sci (2016) 0.75
MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells. Oncotarget (2016) 0.75
Nucleotide Analogues as Probes for DNA and RNA Polymerases. Curr Protoc Chem Biol (2010) 0.75
Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies. Anticancer Drugs (2015) 0.75
Advanced non-small cell lung carcinoma: the emerging role of docetaxel. Invest New Drugs (2000) 0.75
Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes. Med Sci Monit (2017) 0.75
The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells. Leuk Lymphoma (2017) 0.75
Glycolysis inhibition for anticancer treatment. Oncogene (2006) 6.55
Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A (1998) 3.23
Gene expression profiling of cells, tissues, and developmental stages of the nematode C. elegans. Cold Spring Harb Symp Quant Biol (2003) 3.22
Protein secondary structures in water from second-derivative amide I infrared spectra. Biochemistry (1990) 2.69
Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol (1995) 2.57
CpG ODN-induced matrix metalloproteinase-13 expression is mediated via activation of the ERK and NF-κB signalling pathways in odontoblast cells. Int Endod J (2013) 2.03
Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression. Oncogene (2010) 1.88
The diverse roles of J-proteins, the obligate Hsp70 co-chaperone. Rev Physiol Biochem Pharmacol (2006) 1.83
Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs. Neurology (2006) 1.69
Telephone assistance for smoking cessation: one year cost effectiveness estimations. Tob Control (2004) 1.64
G alpha(o) is necessary for muscarinic regulation of Ca2+ channels in mouse heart. Proc Natl Acad Sci U S A (1997) 1.48
Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol (2001) 1.47
Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke (2000) 1.40
Heterogeneous nuclear ribonucleoprotein A1 regulates RNA synthesis of a cytoplasmic virus. EMBO J (2000) 1.38
Priming of insulin granules for exocytosis by granular Cl(-) uptake and acidification. J Cell Sci (2001) 1.37
The effects of alcohols on lipid bilayers: a spin label study. Biochim Biophys Acta (1972) 1.33
Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol (2005) 1.32
Preclinical characteristics of gemcitabine. Anticancer Drugs (1995) 1.31
MAP 30: a new inhibitor of HIV-1 infection and replication. FEBS Lett (1990) 1.30
Endothelial nitric oxide synthase gene-deficient mice demonstrate marked retardation in postnatal bone formation, reduced bone volume, and defects in osteoblast maturation and activity. Am J Pathol (2001) 1.29
Polypyrimidine tract-binding protein binds to the leader RNA of mouse hepatitis virus and serves as a regulator of viral transcription. J Virol (1999) 1.28
Genome-wide analyses on loss of heterozygosity in hepatocellular carcinoma in Southern China. J Hepatol (2001) 1.24
Muscarinic cholinergic regulation of cardiac myocyte ICa-L is absent in mice with targeted disruption of endothelial nitric oxide synthase. Proc Natl Acad Sci U S A (1998) 1.23
A partial GDNF depletion leads to earlier age-related deterioration of motor function and tyrosine hydroxylase expression in the substantia nigra. Exp Neurol (2006) 1.23
2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest. Mol Pharmacol (2001) 1.22
Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway. Cell Death Differ (2013) 1.22
Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia (2008) 1.21
Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood (1997) 1.20
Increased mitochondrial biogenesis in primary leukemia cells: the role of endogenous nitric oxide and impact on sensitivity to fludarabine. Leukemia (2004) 1.20
Evolutionary characterization of recent human H3N2 influenza A isolates from Japan and China: novel changes in the receptor binding domain. Arch Virol (1996) 1.19
Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells. Leukemia (2005) 1.18
Identification of an N-terminal amino acid of the CLC-3 chloride channel critical in phosphorylation-dependent activation of a CaMKII-activated chloride current. J Physiol (2004) 1.17
Divergent functional properties of the ribosome-associated molecular chaperone Ssb compared with other Hsp70s. Mol Biol Cell (2001) 1.17
Texas Tobacco Prevention Pilot Initiative: processes and effects. Health Educ Res (2004) 1.14
S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. Cancer Res (2001) 1.13
Protection against TNF-induced lethal shock by soluble guanylate cyclase inhibition requires functional inducible nitric oxide synthase. Immunity (2000) 1.10
Interaction of p53 and DNA-PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage. Cancer Res (2001) 1.09
TAP 29: an anti-human immunodeficiency virus protein from Trichosanthes kirilowii that is nontoxic to intact cells. Proc Natl Acad Sci U S A (1991) 1.09
Cloning and characterization of a cDNA encoding beta-amyrin synthase involved in glycyrrhizin and soyasaponin biosyntheses in licorice. Biol Pharm Bull (2001) 1.06
Different vasculoprotective roles of NO synthase isoforms in vascular lesion formation in mice. Arterioscler Thromb Vasc Biol (2000) 1.06
Distribution of small integrin-binding ligand, N-linked glycoproteins (SIBLING) in the condylar cartilage of rat mandible. Int J Oral Maxillofac Surg (2010) 1.04
Distinct long-term neurocognitive outcomes after equipotent sevoflurane or isoflurane anaesthesia in immature rats. Br J Anaesth (2013) 1.04
Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J Clin Oncol (2000) 1.02
Anti-HIV plant proteins catalyze topological changes of DNA into inactive forms. Biofactors (1992) 1.02
Redox-dependent changes in beta-extended chain and turn structures of cytochrome c in water solution determined by second derivative amide I infrared spectra. Biochemistry (1992) 1.01
A new class of anti-HIV agents: GAP31, DAPs 30 and 32. FEBS Lett (1991) 1.01
Insulin-receptor and apolipoprotein genes contribute to development of NIDDM in Chinese Americans. Diabetes (1989) 1.00
Metabolism and action of fludarabine phosphate. Semin Oncol (1990) 0.99
Elimination of aggressive behavior in male mice lacking endothelial nitric oxide synthase. J Neurosci (1999) 0.98
Reduced expression of the μ opioid receptor in some, but not all, brain regions in mice with OPRM1 A112G. Neuroscience (2012) 0.98
Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol (1999) 0.97
Lymphangioma circumscriptum of scrotum of late onset. Indian J Dermatol Venereol Leprol (2010) 0.97
Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol (1993) 0.96
Purine and pyrimidine nucleoside analogs. Cancer Chemother Biol Response Modif (2001) 0.95
The conserved cysteine 7.38 residue is differentially accessible in the binding-site crevices of the mu, delta, and kappa opioid receptors. Biochemistry (2000) 0.95
Mitomycin C reduces haze formation in rabbits after excimer laser photorefractive keratectomy. J Refract Surg (2001) 0.95
Inverse agonist up-regulates the constitutively active D3.49(164)Q mutant of the rat mu-opioid receptor by stabilizing the structure and blocking constitutive internalization and down-regulation. Mol Pharmacol (2001) 0.95
Surface analyses of micro-arc oxidized and hydrothermally treated titanium and effect on osteoblast behavior. J Biomed Mater Res A (2004) 0.94
Predictors of tobacco sales to minors. Prev Med (1997) 0.94
Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C. Leukemia (2006) 0.92
L-NA-sensitive rCBF augmentation during vibrissal stimulation in type III nitric oxide synthase mutant mice. J Cereb Blood Flow Metab (1996) 0.91
Increased susceptibility to development of triggered activity in myocytes from mice with targeted disruption of endothelial nitric oxide synthase. J Mol Cell Cardiol (2000) 0.91
Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step. Cancer Res (1999) 0.90
Effects of brain-derived neurotrophic factor on dopaminergic function and motor behavior during aging. Genes Brain Behav (2010) 0.90
Constitutive activation of the mu opioid receptor by mutation of D3.49(164), but not D3.32(147): D3.49(164) is critical for stabilization of the inactive form of the receptor and for its expression. Biochemistry (2001) 0.90
DNA damage-induced phosphorylation of p53 at serine 20 correlates with p21 and Mdm-2 induction in vivo. Oncogene (2000) 0.90
[Anti-inflammatory, analgesic and sedative effects of Leontice kiangnanensis P.L. Chiu]. Zhongguo Zhong Yao Za Zhi (1991) 0.89
Isolation and characterization of a gene encoding DNA topoisomerase I in Drosophila melanogaster. Nucleic Acids Res (1992) 0.89
High-performance liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells. J Chromatogr B Biomed Sci Appl (2000) 0.89
Biomarker discovery: identification of a growth factor gene signature. Clin Pharmacol Ther (2009) 0.89
Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma (1993) 0.89
Ultrasound triggered cell death in vitro with doxorubicin loaded poly lactic-acid contrast agents. Ultrasonics (2009) 0.89
Regulation of switching and production of IgA in human B cells in donors with duplicated alpha1 genes. Eur J Immunol (2001) 0.89
Genome-wide allelotype analysis of sporadic primary nasopharyngeal carcinoma from southern China. Int J Oncol (2000) 0.89
Comparison of the amino acid residues in the sixth transmembrane domains accessible in the binding-site crevices of mu, delta, and kappa opioid receptors. Biochemistry (2001) 0.89
[A preliminary report of the effect of levodopa and carbidopa for childhood amblyopia]. Yan Ke Xue Bao (1998) 0.88
Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC). Biochem Pharmacol (2001) 0.87
Mitochondrial dysfunction resulting from loss of cytochrome c impairs radiation-induced bystander effect. Br J Cancer (2009) 0.87
Nitric oxide mediates 17beta-estradiol-stimulated human and rodent osteoblast proliferation and differentiation. Biochem Biophys Res Commun (2000) 0.87
Therapy-induced expression of NF-kappaB portends poor prognosis in patients with localized esophageal cancer undergoing preoperative chemoradiation. Dis Esophagus (2008) 0.87
Cellular pharmacodynamics of anticancer drugs. Semin Oncol (1993) 0.87
Dislocation-controlled perforated layer phase in a PEO- b-PS diblock copolymer. Phys Rev Lett (2001) 0.86
Gemcitabine in hematologic malignancies. Curr Opin Oncol (2001) 0.86
Preoperative T staging of advanced gastric cancer using double contrast-enhanced ultrasound. Ultraschall Med (2012) 0.85
Cytotoxicity, metabolism, and mechanisms of action of 2',2'-difluorodeoxyguanosine in Chinese hamster ovary cells. Cancer Res (1995) 0.85
Distribution and ultrastructural localization of GEC1 in the rat CNS. Neuroscience (2006) 0.85
Role of p53 in cellular response to anticancer nucleoside analog-induced DNA damage. Int J Mol Med (2000) 0.85
Mammalian mitochondrial mutants selected for resistance to the cytochrome b inhibitors HQNO or myxothiazol. Somatic Cell Genet (1983) 0.84
Quality of life and social environment as reported by Chinese immigrants with non-insulin-dependent diabetes mellitus. Diabetes Educ (1997) 0.84
Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphatein primary human leukemia cells. Clin Cancer Res (1997) 0.84
Modelling evolution and the evolving mechanical environment of saccular cerebral aneurysms. Biomech Model Mechanobiol (2010) 0.84
Functional compartmentation of dCTP pools. Preferential utilization of salvaged deoxycytidine for DNA repair in human lymphoblasts. J Biol Chem (1995) 0.84
Anatomic variations in radial and ulnar lengths in the wrists of Chinese. Clin Orthop Relat Res (1971) 0.84
Dual mode of inhibition of purified DNA ligase I from human cells by 9-beta-D-arabinofuranosyl-2-fluoroadenine triphosphate. J Biol Chem (1992) 0.84
Enhanced 2.0 microm emission and gain coefficient of transparent glass ceramic containing BaF2: Ho3+,Tm3+ nanocrystals. Opt Express (2009) 0.84